Zimlovisertib

DB15143InvestigationalSmall molecule

PF-06650833 is under investigation in clinical trial NCT02609139 (Study to Evaluate Pharmacokinetics of A Modified Release Formulation of PF-06650833 in Healthy Subjects).

Mechanism: Pharmacologically active on Interleukin-1 receptor-associated kinase 4
Curator reviewed
Formula / weight: C₁₈H₂₀FN₃O₄ · 361.373 g/mol (avg)
Code names: PF-06650833

Resolves to

Compound

UNIIS3F315JJXICAS1817626-54-2ChEMBLCHEMBL4081711

Structure

InChIKeyJKDGKIBAOAFRPJ-ZBINZKHDSA-NSMILESCC[C@H]1[C@@H](COC2=C3C=C(OC)C(=CC3=CC=N2)C(N)=O)NC(=O)[C@H]1F

Targets

Q9NWZ3IRAK4

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

7Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Zimlovisertib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account